Pharmaceutical Executive-01-01-2019

In this Q&A, American-born David Meek, today CEO of Paris-based multinational Ipsen, discusses the drugmaker's bold global expansion and R&D transformation-driven by revamped leadership, a biotech mindset, and promoting external innovation.

CDER priorities for 2019 include opioids, quality, safety, and innovation.

Pharma companies are increasingly expanding their portfolios into digital health solutions. To find the right partners, there are several key considerations that inform their evaluation and selection.

Leaders at Novartis share how the big pharma is laying the foundations for a potential new operating model as a "medicines and data science company."

Being more human in brand engagement doesn’t mean being less transparent

Click the title above to open the Pharmaceutical January 2019 issue in an interactive PDF format.

Despite market access hurdles, Turkey’s pharmaceutical market holds tremendous growth potential-in both value and volume. But will the country be able to take that final step in creating a regulatory and economic environment that is conducive to further upward development?